Table of Content

Open Access iconOpen Access

ARTICLE

Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials

Guanling Chen1, Zhaoze Guo1, Minfeng Liu, Guangyu Yao, Jianyu Dong, Jingyun Guo, Changsheng Ye

Breast Center, Nanfang Hospital, Southern Medical University, Guangzhou, P.R. China
1 These authors provided equal contribution to this work.

Oncology Research 2017, 25(9), 1567-1578. https://doi.org/10.3727/096504017X14897173032733

Abstract

Capecitabine has consistently demonstrated high efficacy and acceptable tolerability in salvage chemotherapy for advanced breast cancer. However, there remains no consensus on its role in adjuvant chemotherapy for early breast cancer (EBC). To estimate the value of capecitabine-based combination adjuvant treatment in EBC, eight randomized controlled trials with 14,072 participants were analyzed. The efficacy and safety outcomes included disease-free survival (DFS), overall survival (OS), relapse, breast cancer-specific survival (BCSS), and grades 3–5 adverse events. Capecitabine-based combination adjuvant chemotherapy demonstrated a 16% increase in BCSS (HR = 0.84, 95% CI = 0.71–0.98, p = 0.03) in the overall analysis and a 22% improvement in DFS (HR = 0.78, 95% CI = 0.64–0.96, p = 0.02) in the hormone receptor-negative (HR− ) subgroup. However, there were no significant differences in DFS (HR = 0.96, 95% CI = 0.89–1.05, p = 0.38), OS (HR = 0.91, 95% CI = 0.82–1.00, p = 0.06), or relapse between capecitabine-based and capecitabine-free combination adjuvant chemotherapy. Analogous results were observed in the subgroup analyses of HR+ , HER2- , HER2+ , and triplenegative EBC. Regarding safety, reduced myelosuppression and hand–foot syndrome development were observed in capecitabine-treated patients. Capecitabine-based combination adjuvant chemotherapy might provide some BCSS benefit compared with capecitabine-free regimens in EBC, but the absolute survival gain is small, and the survival benefit appears to be restricted to patients with HR− EBC, which may indicate a target population for capecitabine-based combination adjuvant chemotherapy.

Keywords


Cite This Article

APA Style
Chen, G., Guo, Z., Liu, M., Yao, G., Dong, J. et al. (2017). Clinical value of capecitabine-based combination adjuvant chemotherapy in early breast cancer: A meta-analysis of randomized controlled trials. Oncology Research, 25(9), 1567-1578. https://doi.org/10.3727/096504017X14897173032733
Vancouver Style
Chen G, Guo Z, Liu M, Yao G, Dong J, Guo J, et al. Clinical value of capecitabine-based combination adjuvant chemotherapy in early breast cancer: A meta-analysis of randomized controlled trials. Oncol Res. 2017;25(9):1567-1578 https://doi.org/10.3727/096504017X14897173032733
IEEE Style
G. Chen et al., "Clinical Value of Capecitabine-Based Combination Adjuvant Chemotherapy in Early Breast Cancer: A Meta-Analysis of Randomized Controlled Trials," Oncol. Res., vol. 25, no. 9, pp. 1567-1578. 2017. https://doi.org/10.3727/096504017X14897173032733



cc This work is licensed under a Creative Commons Attribution 4.0 International License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
  • 28

    View

  • 24

    Download

  • 0

    Like

Share Link